NASH (非酒精性脂肪性肝病炎)大鼠肠道的病理变化
Pathological Changes of Intestinal Tract in NASH Rats
DOI: 10.12677/ACM.2020.1011408, PDF, HTML, XML, 下载: 599  浏览: 741 
作者: 郭 涛, 戴光荣：延安大学附属医院，陕西 延安
关键词: 非酒精性；大鼠肠道；脂肪性；肝病炎；病理变化；Nonalcoholic； Rat Intestine； Fatty； Hepatopathy Inflammation； Pathological Changes
摘要: 总结研究非酒精性脂肪性肝病炎的研究进展。通过查阅国内外的数据文献，以非酒精性脂肪性肝病炎病理变化、临床表现等作为综述重点，通过以大鼠肠道的病理变化为研究基础，总结出非酒精性脂肪性肝病炎的发病机制、临床表现以及治疗方式，为非酒精性脂肪性肝病炎的临床发展夯实基础。
Abstract: The article is to summarize the research progress of nonalcoholic fatty liver disease. Based on the pathological changes of rat intestine, the pathogenesis, clinical manifestations and treatment of NAFLD were summarized, which laid a solid foundation for the clinical development of NAFLD.
文章引用：郭涛, 戴光荣. NASH (非酒精性脂肪性肝病炎)大鼠肠道的病理变化[J]. 临床医学进展, 2020, 10(11): 2684-2690. https://doi.org/10.12677/ACM.2020.1011408

参考文献

[1] 傅建, 齐洁, 张波, 张钧. 游泳运动对高脂引起的大鼠非酒精性脂肪肝的预防作用及机制[J]. 体育与科学, 2019, 40(3): 108-115.
[2] 金军, 刘吉祥, 易鸣. 黄连素对高脂饮食诱导非酒精性脂肪性肝病小鼠肝脂毒性的保护作用及相关机制研究[J]. 临床和实验医学杂志, 2019(11): 1124-1128.
[3] 代静. 疏肝理脾方对非酒精性脂肪性肝炎大鼠肠道菌群的影响研究[D]: [硕士学位论文]. 长沙: 湖南中医药大学, 2019.
[4] 陈梦婷. “肠道菌群–内源性大麻素系统”在白藜芦醇防治NAFLD中的作用及机制研究[D]: [博士学位论文]. 重庆: 中国人民解放军陆军军医大学, 2019.
[5] 瞿娟, 吴双贵, 吴甜, 刘智慧, 刘梦姣, 黄小飞, 李春艳. 黄瓜香对高脂饲料诱导的大鼠非酒精性脂肪肝保护作用研究[J]. 临床医学进展, 2019, 9(1): 7-12.
[6] 姜云. 丹皮酚对非酒精性脂肪肝大鼠肠道菌群及炎症因子影响的研究[D]: [硕士学位论文]. 合肥: 安徽中医药大学, 2019.
[7] 曹颖, 谢雯. 非酒精性脂肪性肝病发病机制研究[J]. 中国临床医生杂志, 2020, 48(1): 12-14.
[8] 任习芳, 张丽静. 益生菌制剂辅助治疗中重度脂肪肝患者肠功能紊乱的临床疗效[J]. 医药导报, 2019, 38(5): 603-606.
[9] 杨清荣, 吉木斯, 陈伟钊. 益生菌联合多烯磷脂酰胆碱治疗非酒精性脂肪肝的临床疗效分析[J]. 中国实用医药, 2019, 14(8): 93-94.
[10] 高琦. 肠道益生菌辅治对非酒精性脂肪性肝硬化患者糖脂代谢、氧化损伤和肝功能的影响[J]. 微量元素与健康研究, 2019, 36(2): 20-21.
[11] 李亚男, 马晓峰, 王小英, 秦静. 乳杆菌联合甘露寡糖对非酒精性小鼠脂肪肝的影响[J]. 广东医学, 2019, 40(3): 344-347.
[12] 刘贝贝, 徐可树. 非酒精性脂肪性肝病的药物治疗[J]. 中国实用内科杂志, 2019, 39(3): 214-217.
[13] 邵幼林, 范建高. 非酒精性脂肪性肝病的流行现状与危害[J]. 中华肝脏病杂志, 2019, 27(1): 10-13.
[14] Chi, Y.L., Lin, Y., Lu, Y.Y., Huang, Q.S., Ye, G.Z. and Dong, S.J. (2019) Gut Microbiota Dysbiosis Correlates with a Low-Dose PCB126-Induced Dyslipidemia and Non-Alcoholic Fatty Liver Disease. Science of the Total Environment, 653, 274-282. https://doi.org/10.1016/j.scitotenv.2018.10.387
[15] Li, F., Sun, G., Wang, Z.K., Wu, W.M., Guo, H., Peng, L.H., Wu, L.L., Guo, X. and Yang, Y.S. (2018) Characteristics of Fecal Microbiota in Non-Alcoholic Fatty Liver Disease Patients. Science China (Life Sciences), 61, 770-778. https://doi.org/10.1007/s11427-017-9303-9
[16] 朱文正. 长期口服益生菌片对非酒精性脂肪性肝病患者肠道菌落和血清肝纤维化指标水平的影响[J]. 现代实用医学, 2018, 30(10): 57-59.
[17] 祝娟娟, 程明亮, 赵雪珂, 穆茂. 蓝莓联合益生菌通过IL-22调控的JAK1/STAT3/BAX通路改善非酒精性脂肪性肝病的作用机制[J]. 临床肝胆病杂志, 2018, 34(9): 128-136.
[18] 曹少锋, 梅璐, 黄煌, 孙向东, 蒋杰, 任士萌, 赵锐豪, 郑鹏远. 降脂益生菌调节胆固醇代谢改善小鼠非酒精性脂肪肝[J]. 中国微生态学杂志, 2018, 30(8): 869-874.
[19] 谭利莎, 邓春玲, 李玲艳, 杨冰, 钟森. 基于“脾不散精”探讨非酒精性脂肪性肝病治疗思路[J]. 世界最新医学信息文摘, 2018(45): 223-223.
[20] 张园园, 严君君, 张培, 周希乔. 黄连素调节肠道菌群减轻非酒精性脂肪性肝病肝脏炎症的实验研究[J]. 胃肠病学, 2018, 23(4): 209-215.
[21] 费亚军, 费璇. 肾俞五十七穴电针治疗非酒精性脂肪肝的疗效及对肝脏CT值的影响[J]. 针灸临床杂志, 2018, 34(3): 62-65.
[22] Zhu, S.Y., Jiang, N., Yang, J., Tu, J., Zhou, Y., Xiao, X. and Dong, Y. (2018) Silybum Marianum Oil Attenuates Hepatic Steatosis and Oxidative Stress in High Fat Diet-Fed Mice. Biomedicine & Pharmacotherapy, 100, 191-197. https://doi.org/10.1016/j.biopha.2018.01.144
[23] Wattacheril, J., Issa, D. and Sanyal, A. (2018) Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies. Annual Review of Pharmacology and Toxicology, 58, 649-662. https://doi.org/10.1146/annurev-pharmtox-010617-052545
[24] Lim, H.-W. and Bernstein, D.E. (2018) Risk Factors for the Development of Nonalcoholic Fatty Liver Disease/Nonal- coholic Steatohepatitis, Including Genetics. Clinics in Liver Disease, 22, 39-57. https://doi.org/10.1016/j.cld.2017.08.008
[25] Vilar-Gomez, E. and Chalasani, N. (2018) Non-Invasive Assessment of Non-Alcoholic Fatty Liver Disease: Clinical Prediction Rules and Blood-Based Biomarkers. Journal of Hepatology, 68, 305-315. https://doi.org/10.1016/j.jhep.2017.11.013
[26] Loomba, R. (2018) Role of Imaging-Based Biomarkers in NAFLD: Recent Advances in Clinical Application and Future Research Directions. Journal of Hepatology, 68, 296-304. https://doi.org/10.1016/j.jhep.2017.11.028
[27] 崔翔. 消脂益肝方防治高脂饮食诱导的大鼠非酒精性脂肪性肝病的机制研究[D]: [博士学位论文]. 武汉: 湖北中医药大学, 2017.
[28] Faraj, T.A., McLaughlin, C.L. and Erridge, C. (2017) Host Defenses against Metabolic Endotoxaemia and Their Impact on Lipopolysaccharide Detection. International Reviews of Immunology, 36, 125-144. https://doi.org/10.1080/08830185.2017.1280483
[29] Cobbina, E. and Akhlaghi, F. (2017) Non-Alcoholic Fatty Liver Disease (NAFLD)—Pathogenesis, Classification, and Effect on Drug Metabolizing Enzymes and Transporters. Drug Metabolism Reviews, 49, 197-211. https://doi.org/10.1080/03602532.2017.1293683
[30] Mann, J.P., et al. (2017) Clinical Implications of Understanding the Association between Oxidative Stress and Pediatric NAFLD. Expert Review of Gastroenterology & Hepatology, 11, 371-382. https://doi.org/10.1080/17474124.2017.1291340
[31] Rotman, Y. and Sanyal, A.J. (2017) Current and Upcoming Pharmacotherapy for Non-Alcoholic Fatty Liver Disease. Gut, 66, 180-190. https://doi.org/10.1136/gutjnl-2016-312431
[32] 肖伟松, 乐滢玉, 曾胜澜, 覃小宾, 吴聪, 毛德文. 非酒精性脂肪性肝病的发病机制研究进展[J]. 临床肝胆病杂志, 2020, 36(8): 1874-1879.
[33] 马富超, 张泉洋, 王帅, 吴崇明, 郭鹏. 非酒精性脂肪性肝病动物模型研究进展[J]. 国际药学研究杂志, 2017, 44(5): 409-414.
[34] 侯洪涛, 裘艳梅, 胡义亭, 张建, 李月芹. 姜黄素对高脂饲料喂养大鼠肠道菌群的影响[J]. 现代预防医学, 2017, 44(18): 3310-3312+3341.
[35] 韩本丽. 二甲双胍联合盐酸小檗碱治疗非酒精性脂肪肝疗效及对白细胞介素-17与转化生长因子-β水平影响[J]. 现代中西医结合杂志, 2017, 26(5): 496-499.
[36] 罗莉川. “脂肝方”对NASH大鼠肝细胞线粒体选择性自噬及其碎片降解机制的影响[D]: [硕士学位论文]. 南宁: 广西中医药大学, 2017.
[37] 徐三鹏. 慈菇消脂胶囊对非酒精性脂肪性肝病大鼠PPARa及CAT表达影响的研究[D]: [硕士学位论文]. 兰州: 甘肃中医药大学, 2017.
[38] Fonseca, J., Nunes, G., Fonseca, C., Canhoto, M., Barata, A.T. and Santos, C.A. (2017) Comment to: “EASL-EASD- EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease”. Journal of Hepatology, 64, 1388-1402. https://doi.org/10.1016/j.jhep.2016.10.036
[39] Xu, J., Chen, H.B. and Li, S.L. (2017) Understanding the Molecular Mechanisms of the Interplay between Herbal Medicines and Gut Microbiota. Medicinal Research Reviews, 37, 1140-1185. https://doi.org/10.1002/med.21431
[40] Hu, Q.L., Zhuo, Z., Fang, S.L., Zhang, Y.W. and Feng, J. (2017) Phytosterols Improve Immunity and Exert Anti-Inflammatory Activity in Weaned Piglets. Journal of the Science of Food and Agriculture, 97, 4103-4109. https://doi.org/10.1002/jsfa.8277
[41] 张静怡. 非酒精性脂肪性肝病对肠道微生物、代谢产物以及肠道通透性影响的研究[D]: [硕士学位论文]. 上海: 上海交通大学, 2017.
[42] Babkova, K., Korabecny, J., Soukup, O., Nepovimova, E., Jun, D. and Kuca, K. (2017) Prolyl Oligopeptidase and Its Role in the Organism: Attention to the Most Promising and Clinically Relevant Inhibitors. Future Medicinal Chemistry, 9, 1015-1038. https://doi.org/10.4155/fmc-2017-0030
[43] Jiang, Y., Han, T., Zhang, Z.-G., Li, M., Qi, F.-X., Zhang, Y. and Ji, Y.-L. (2017) Potential Role of Thymosin Beta 4 in the Treatment of Nonalcoholic Fatty Liver Disease. Chronic Diseases and Translational Medicine, 20, 1e4. https://doi.org/10.1016/j.cdtm.2017.06.003
[44] Li, G.Y., Zhou, F., Chen, Y., Zhang, W.G. and Wang, N. (2017) Kukoamine A Attenuates Insulin Resistance and Fatty Liver through Downregulation of Srebp-1c. Biomedicine & Pharmacotherapy, 89, 536-543. https://doi.org/10.1016/j.biopha.2017.02.024
[45] 龚世梅, 舒发明, 冯全生. 中药复方治疗非酒精性脂肪肝研究进展[J]. 云南中医中药杂志, 2016, 37(1): 83-85.
[46] 麦静愔, 高月求, 蔡峥, 方蔓倩. 参葛方对非酒精性脂肪性肝炎大鼠肠道黏膜屏障损伤和紧密连接蛋白Occludin表达的影响[J]. 中西医结合肝病杂志, 2016, 26(4): 228-230.
[47] 张志勇, 王建钢. 自拟荷叶丹参饮治疗非酒精性脂肪性肝病临床观察[J]. 四川中医, 2016(8): 111-113.
[48] 史晓伟, 王一强, 张玉香, 王俊喹. 清肝祛湿活血方治疗非酒精性脂肪肝的疗效评价[J]. 中国实验方剂学杂志, 2016, 22(15): 181-184.
[49] 唐金模, 梁惠卿, 王宏国, 林曼婷, 张利敏, 陈少东. 皂术茵陈方治疗非酒精性脂肪性肝炎的临床疗效及对游离脂肪酸和TNF-α的影响[J]. 中国中西医结合杂志, 2016, 36(5): 544-548.
[50] 王文成. 海兔素对慢性酒精性肝损伤大鼠TLR4信号转导通路和肠道菌群的影响[D]: [博士学位论文]. 青岛: 青岛大学, 2016.

为你推荐